JP2025513345A5 - - Google Patents
Info
- Publication number
- JP2025513345A5 JP2025513345A5 JP2024561810A JP2024561810A JP2025513345A5 JP 2025513345 A5 JP2025513345 A5 JP 2025513345A5 JP 2024561810 A JP2024561810 A JP 2024561810A JP 2024561810 A JP2024561810 A JP 2024561810A JP 2025513345 A5 JP2025513345 A5 JP 2025513345A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- glp
- exendin
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2022-0047662 | 2022-04-18 | ||
| KR20220047662 | 2022-04-18 | ||
| PCT/KR2023/005198 WO2023204556A1 (ko) | 2022-04-18 | 2023-04-18 | 장질환의 예방 또는 치료를 위한 GLP-2와, 인슐린 분비 펩타이드, TNFα 억제제, 또는 이 둘 모두의 병용 요법 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025513345A JP2025513345A (ja) | 2025-04-24 |
| JP2025513345A5 true JP2025513345A5 (https=) | 2026-04-27 |
Family
ID=88420096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024561810A Pending JP2025513345A (ja) | 2022-04-18 | 2023-04-18 | 腸疾患の予防又は治療のためのＧＬＰ－２と、インスリン分泌ペプチド、ＴＮＦα抑制剤、又はその両方の併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250276044A1 (https=) |
| EP (1) | EP4512414A4 (https=) |
| JP (1) | JP2025513345A (https=) |
| KR (1) | KR20230149258A (https=) |
| CN (1) | CN119325387A (https=) |
| AU (1) | AU2023256431A1 (https=) |
| CA (1) | CA3249442A1 (https=) |
| IL (1) | IL316444A (https=) |
| MX (1) | MX2024012860A (https=) |
| WO (1) | WO2023204556A1 (https=) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| CN102325539A (zh) * | 2008-12-19 | 2012-01-18 | 印第安纳大学研究及科技有限公司 | 基于酰胺的胰高血糖素超家族肽前药 |
| US20180280480A1 (en) * | 2014-10-31 | 2018-10-04 | Gubra Aps | Compositions and peptides having dual glp-1r and glp-2r agonist activity |
| KR101825048B1 (ko) * | 2014-12-31 | 2018-02-05 | 주식회사 제넥신 | GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도 |
| CA3084326A1 (en) * | 2017-09-28 | 2019-04-04 | Jaehyuk Choi | Long-acting conjugates of glp-2 derivatives |
| EP4126004A1 (en) * | 2020-03-30 | 2023-02-08 | Zealand Pharma A/S | Agonist combination |
| AU2021409610A1 (en) * | 2020-12-24 | 2023-07-06 | Hanmi Pharm. Co., Ltd. | Combination therapy of insulinotropic peptide and glp-2, for preventing or treating short bowel syndrome |
-
2023
- 2023-04-18 CA CA3249442A patent/CA3249442A1/en active Pending
- 2023-04-18 CN CN202380045504.2A patent/CN119325387A/zh active Pending
- 2023-04-18 IL IL316444A patent/IL316444A/en unknown
- 2023-04-18 JP JP2024561810A patent/JP2025513345A/ja active Pending
- 2023-04-18 EP EP23792132.5A patent/EP4512414A4/en active Pending
- 2023-04-18 KR KR1020230050914A patent/KR20230149258A/ko active Pending
- 2023-04-18 WO PCT/KR2023/005198 patent/WO2023204556A1/ko not_active Ceased
- 2023-04-18 US US18/857,479 patent/US20250276044A1/en active Pending
- 2023-04-18 AU AU2023256431A patent/AU2023256431A1/en active Pending
-
2024
- 2024-10-17 MX MX2024012860A patent/MX2024012860A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102310389B1 (ko) | Ｇｉｐ-ｇｌｐ-1 이원 효능제 화합물 및 방법 | |
| KR102311517B1 (ko) | 옥신토모듈린과 면역글로불린 단편을 포함하는 단백질 결합체의 액상 제제 | |
| CN104918632B (zh) | 治疗糖尿病或糖胖病的包括胃泌酸调节素类似物的组合物 | |
| AU2015242657B2 (en) | Method for improving solubility of protein and peptide by using immunoglobulin Fc fragment linkage | |
| JP2014141500A (ja) | グルカゴン／ｇｌｐ−１受容体コアゴニスト | |
| CN110099692A (zh) | 作为神经肽y受体调节剂的环状肽酪氨酸酪氨酸化合物 | |
| CA2732949A1 (en) | Analogues of glucose-dependent insulinotropic polypeptide | |
| BR122022025353B1 (pt) | Composição e uso de conjugado de derivado de oxintomodulina para a prevenção ou tratamento de hiperlipidemia, doença hepática gordurosa ou arteriosclerose | |
| CA2965560A1 (en) | Compositions and peptides having dual glp-1r and glp-2r agonist activity | |
| JP2022551233A (ja) | 異なる構造のｇｌｐ－１アナログペプチド修飾二量体およびその調製方法のｉｉ型糖尿病の治療における用途 | |
| JP2022171653A (ja) | グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体又はその結合体の肝疾患に対する治療的使用 | |
| JP2023525260A (ja) | 二重受容体アゴニスト作用を有するポリペプチド誘導体及びその用途 | |
| AU2016332062A1 (en) | Treatment of bile acid disorders | |
| JP2025525218A (ja) | インクレチンアナログおよびその使用 | |
| WO2020098657A1 (zh) | 具有双重受体激动作用的胰高血糖素衍生肽及其用途 | |
| JP2023538236A (ja) | グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体を含む血圧降下用薬学組成物 | |
| KR20210116322A (ko) | 신규 이중 특이성 단백질 및 그의 용도 | |
| WO2004048401A1 (ja) | ペプチド及びこれを含む医薬組成物 | |
| JP2025513345A5 (https=) | ||
| RU2024132221A (ru) | Комбинированная терапия, включающая GLP-2 с инсулинотропным пептидом, ингибитором TNFα или с ними обоими, для предупреждения или лечения | |
| US20260028397A1 (en) | Methods of treating ankylosing spondylitis | |
| KR20220010462A (ko) | 3중 작용성 지속형 결합체 또는 3중 작용제를 포함하는 조합물의 치료학적 용도 | |
| CN115776880A (zh) | 液体制剂 | |
| JP2025513345A (ja) | 腸疾患の予防又は治療のためのＧＬＰ－２と、インスリン分泌ペプチド、ＴＮＦα抑制剤、又はその両方の併用療法 | |
| KR20170100908A (ko) | 지속형 fgf21 수용체 아고니스트 결합체 및 지속형 인슐린 분비 펩타이드 결합체를 포함하는 대사증후군 치료용 조성물 |